CDX-1140

Monoclonal antibody targets CD40 via activation

Developed for: epithelial neoplasm · non-small cell lung carcinoma · pancreatic adenocarcinoma · basal cell carcinoma · bile duct cancer · bone sarcoma · breast cancer · breast carcinoma
+37 more
· cholangiocarcinoma · chronic lymphocytic leukemia/small lymphocytic lymphoma · colorectal cancer · cutaneous neuroendocrine carcinoma · diffuse large B-cell lymphoma · endometrial serous adenocarcinoma · esophageal cancer · fallopian tube cancer · fallopian tube endometrioid adenocarcinoma · fallopian tube serous adenocarcinoma · follicular lymphoma · gastric cancer · head and neck cancer · Her2-receptor negative breast cancer · hypopharynx squamous cell carcinoma · laryngeal squamous cell carcinoma · malignant pancreatic neoplasm · MALT lymphoma · mantle cell lymphoma · melanoma · metastatic melanoma · nasal cavity squamous cell carcinoma · nasopharyngeal carcinoma · oral cavity squamous cell carcinoma · oropharynx squamous cell carcinoma · ovarian cancer · ovarian clear cell adenocarcinoma · ovarian endometrioid adenocarcinoma · ovarian serous adenocarcinoma · primary peritoneal carcinoma · primary peritoneal serous adenocarcinoma · renal cell carcinoma · skin squamous cell carcinoma · soft tissue sarcoma · urothelial carcinoma · uveal melanoma · Waldenstrom macroglobulinemia
Investigated by: Celldex Therapeutics · National Cancer Institute (NCI) · Merck Sharp & Dohme LLC · Providence Health & Services · Albert Einstein College of Medicine · Craig L Slingluff, Jr
+10 more
· Gateway for Cancer Research · HiberCell, Inc. · National Cancer Institute (NCI) · National Institutes of Health (NIH) · Roswell Park Cancer Institute · The Foundation for Barnes-Jewish Hospital · United States Department of Defense · University of Southern California · University of Texas Southwestern Medical Center · Washington University School of Medicine

Trials 12

today NCT06980038 · Ph 2 NCT05849480 · Ph 1/2 NCT05231122 · Ph 2 NCT05349890 · Ph 1 NCT04616248 · Ph 1 NCT05484011 · Ph 1 NCT05029999 · Ph 1 NCT04520711 · Ph 1 NCT04536077 · Ph 2 NCT04491084 · Ph 1/2 NCT04364230 · Ph 1/2 NCT03329950 · Ph 1

201820192020202120222023202420252026202720282029203020312032203320342035203620372038203920402041

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 16 trials
Phase 1	NCT05349890	Apr 2023 → Apr 2027 expected	epithelial neoplasm	Providence Health & Services	Active not recruiting	No outcome recorded
Phase 1	NCT04616248	Jan 2023 → Jan 2027 expected	basal cell carcinoma, bone sarcoma, breast carcinoma, cutaneous neuroendocrine carcinoma +3	University of Southern California	Active not recruiting	No outcome recorded
Phase 1	NCT05484011	Dec 2022 → Mar 2024	pancreatic adenocarcinoma	HiberCell, Inc.	Terminated	No outcome recorded Stop: Business
Phase 1	NCT05029999	Apr 2022 → Apr 2028 expected	Her2-receptor negative breast cancer	University of Texas Southwestern Medical Center	Recruiting	No outcome recorded
Phase 1	NCT04520711	Feb 2022 → Dec 2026 expected	epithelial neoplasm	Providence Health & Services	Active not recruiting	No outcome recorded
Phase 1	NCT03329950	Dec 2017 → Sep 2022	MALT lymphoma, Waldenstrom macroglobulinemia, breast cancer, cholangiocarcinoma +16	Celldex Therapeutics	Completed	No outcome recorded
Phase 1/23 trials
Phase 1/2	NCT05849480	May 2024 → Jun 2040 expected	bile duct cancer	National Cancer Institute (NCI)	Recruiting	No outcome recorded
Phase 1/2	NCT04491084	Jan 2021 → Aug 2022	non-small cell lung carcinoma	Albert Einstein College of Medicine	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT04364230	Sep 2020 → Mar 2024	uveal melanoma	Craig L Slingluff, Jr	Completed	No outcome recorded
Phase 23 trials
Phase 2	NCT06980038	May 2026 → Nov 2027 expected	hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, nasal cavity squamous cell carcinoma, nasopharyngeal carcinoma +2	National Cancer Institute (NCI)	Recruiting	No outcome recorded
Phase 2	NCT05231122	Mar 2024 → Mar 2027 expected	endometrial serous adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube serous adenocarcinoma, ovarian clear cell adenocarcinoma +3	Roswell Park Cancer Institute	Recruiting	No outcome recorded
Phase 2	NCT04536077	Aug 2021 → Nov 2023	malignant pancreatic neoplasm	Washington University School of Medicine	Terminated	No outcome recorded

News releases announcing trial results or a regulatory action · 1

Date	Issuer	Release
2020-11-09	Celldex Therapeutics	Results Celldex Presents Data from Oncology Portfolio at SITC 2020 celldex.com ↗ An interim update from the Company’s ongoing Phase 1 study of its CD40 agonist antibody, CDX-1140, and preclinical data from its AXL discovery program were presented at the meeting.

All press releases naming this drug 1 release

Date	Issuer	Release
2020-11-09	Celldex Therapeutics	Celldex Presents Data from Oncology Portfolio at SITC 2020 celldex.com ↗

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 13 sources stand behind the page.

Field	Value	Cited text
Known as	CDX-1140	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05849480 ↗ 11 NCT04536077 ↗ NCT04616248 ↗ NCT03329950 ↗ NCT05484011 ↗ NCT05231122 ↗ NCT06980038 ↗ NCT04520711 ↗ NCT04364230 ↗ NCT05349890 ↗ NCT05029999 ↗ Show 1 more source
Action	Activate	“agonistic CD40 antibody (CDX-1140)” PMID 41775435 ↗ Mar 2026
Modality	Monoclonal antibody	“CDX-1140 (CD40 antibody)” NCT03329950 ↗
Route	Intravenous	“single IV infusion” NCT04536077 ↗
Target	CD40	“agonistic CD40 antibody (CDX-1140)” PMID 41775435 ↗ Mar 2026